EPEREZOLID

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H23FN4O5
Molecular Weight	394.3974
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(N3CCN(CC3)C(=O)CO)C(F)=C2

InChI

InChIKey=SIMWTRCFFSTNMG-AWEZNQCLSA-N

InChI=1S/C18H23FN4O5/c1-12(25)20-9-14-10-23(18(27)28-14)13-2-3-16(15(19)8-13)21-4-6-22(7-5-21)17(26)11-24/h2-3,8,14,24H,4-7,9-11H2,1H3,(H,20,25)/t14-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H23FN4O5
Molecular Weight	394.3974
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9333036
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8834904

Eperezolid is an antibiotic agent developed for the treatment of a wide range of bacterial infections. The drug exerts its action by binding to 50 S ribosome subunit causing the inhibition of protein synthesis in bacterias. Eperezolid was tested in preclinical in vivo models of different becterial diseases in which it was shown to be active.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9333036	Binding Agent 1064		20.0 µM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10582874	Curative		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Novel piperidinyloxy oxazolidinone antimicrobial agents.	2001 Jul 23	11459641
Simple method for the assay of linezolid in Brain Heart Infusion broth by high-performance liquid chromatography.	2004 Jan	14872541
Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions.	2009 Jul	19544480
Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis.	2010	22291495

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Eperezolide was active against all classes of pneumococci, with MIC90s of 0.5 ug/ml.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:36:20 GMT 2023` Edited by `admin` on `Fri Dec 15 15:36:20 GMT 2023`
Record UNII	C460ZSU1OW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EPEREZOLID

Official Name

English

Eperezolid [WHO-DD]

Common Name

English

U-100,592

Code

English

U-100592

Code

English

eperezolid [INN]

Common Name

English

ACETAMIDE, N-((3-(3-FLUORO-4-(4-(HYDROXYACETYL)-1-PIPERAZINYL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, (S)-

Common Name

English

EPEREZOLID [USAN]

Common Name

English

N-[[(S)-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C258